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Photodynamic activation as a 
molecular switch to promote 
osteoblast cell differentiation via 
AP-1 activation
Toshihiro Kushibiki1,2, Yupeng Tu1, Adnan O. Abu-Yousif1 & Tayyaba Hasan1
In photodynamic therapy (PDT), cells are impregnated with a photosensitizing agent that is activated 
by light irradiation, thereby photochemically generating reactive oxygen species (ROS). The amounts 
of ROS produced depends on the PDT dose and the nature of the photosensitizer. Although high 
levels of ROS are cytotoxic, at physiological levels they play a key role as second messengers in 
cellular signaling pathways, pluripotency, and differentiation of stem cells. To investigate further 
the use of photochemically triggered manipulation of such pathways, we exposed mouse osteoblast 
precursor cells and rat primary mesenchymal stromal cells to low-dose PDT. Our results demonstrate 
that low-dose PDT can promote osteoblast differentiation via the activation of activator protein-1 
(AP-1). Although PDT has been used primarily as an anti-cancer therapy, the use of light as a 
photochemical “molecular switch” to promote differentiation should expand the utility of this 
method in basic research and clinical applications.
Photodynamic therapy (PDT) has been approved for use in several countries for treatment of cancers 
and diseases associated with neovascularization1, including early-stage tumors and precancerous lesions 
in a wide range of tissues2. Multiple clinical studies of PDT, many of which were aimed at optimizing the 
conditions for its use, have been performed around the world.
In PDT, a photosensitizing compound is injected either systemically or directly into the lesion site. 
After the compound has accumulated in the tumor or other target tissue, the site is irradiated with laser 
light of a wavelength that can penetrate the surrounding tissue and activate the photosensitizing agent3. 
The PDT dose is the product of the photosensitizer concentration and the light dose delivered to the 
target and the PDT dose can impact the outcome in cells at a molecular level4. Photochemical activation 
of the compound results in production of reactive oxygen species (ROS)5. Specifically, irradiation excites 
the photosensitizer to an excited singlet state, which can experience one of two fates: decay to the ground 
state by fluorescence, which can be detected for imaging purposes, or electron spin conversion to the 
triplet state, which mediates the therapeutic effects of PDT. Triplet molecules can react with substrates to 
form radicals that interact with oxygen, resulting in macromolecular oxidation with potentially cytotoxic 
effects. Alternatively, the excited triplet state can transfer energy directly to molecular oxygen, forming 
ROS, the most cytotoxic products formed during PDT.
High levels of ROS can cause cell death, but ROS are also important mediators of intracellular signa-
ling. Although detailed mechanism have yet to be unraveled, it is clear that ROS can target signaling at 
multiple levels, from the cell surface to the nucleus6. Receptor kinases and phosphatases, the upstream 
sensors of signaling pathways, are vulnerable to direct oxidation by ROS, which can block or otherwise 
modulate their physiological functions7. For example, growth-factor receptors are often activated by 
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ligand-induced dimerization/oligomerization, leading to autophosphorylation of the cytoplasmic kinase 
domains8. Clustering and activation of such receptors in the absence of ligand have been demonstrated in 
response to UV light9, and this phenomenon is mediated by ROS10. Within the cytoplasm, cellular redox 
state influences the activity of several major pathways11 that control many aspects of cellular metabolism 
and proliferation via regulation of gene expression12. The transcription factors regulated by redox state 
include redox factor-1 (Ref-1), which mediates activation of activator protein-1 (AP-1) (Fos and Jun)13; 
nuclear factor kappa-B (NF-κ B)14; p5315; hypoxia-inducible factor-1α (HIF-1α ) and HIF-like factor16; 
and signal transducer and activator of transcription-3 (STAT-3)17.
A growing body of evidence suggests that ROS serve as important second messengers in pathways 
that regulate proliferation and differentiation. Oxygen tension influences proliferation and pluripotency 
of bone marrow–derived stem cells (BMSCs)18, in which ROS transduce a variety of signals related 
to control of differentiation19. Inhibition of the mitochondrial respiratory chain, which both alters the 
energy budget of the cell and induces ROS generation, enhances the pluripotency of human embryonic 
stem cells20. ROS also appear to be important for differentiation of stem cells into specific lineages, as 
well as activation of environmental responses in these cells. For example, ROS generation is required for 
differentiation of mesenchymal stem cells into adipocytes21 and for hypoxia-induced IL-6 production 
by ES cells22. Several studies have shown that ROS are critically involved in the differentiation of stem 
cells into the cardiac lineage, acting as second messengers in cardiomyocyte differentiation induced by 
both electrical stimuli23 and mechanical strain24; furthermore, ROS play a crucial role in the survival 
and proliferation of stem cell–derived cardiac cells25. Together, these observations demonstrate that ROS 
exert major influences on stem cell pluripotency and differentiation.
We hypothesized that PDT at doses lower than those conventionally used for cancer treatment might 
induce sufficient levels of ROS to influence differentiation without significant cell killing, thereby acceler-
ating the differentiation of pluripotent cells. We tested this idea in osteoblast precursor cells and primary 
mesenchymal stromal cells, and observed that low-dose PDT indeed promoted osteoblast differentiation 
without significant cytotoxicity. We then investigated several signaling pathways potentially involved 
in osteoblast differentiation, and found that the AP-1 transcription factor is involved in mediating the 
effects of low-dose PDT by activation of Fos, Jun, and Fra transcripts.
Results
Evaluation of osteoblast differentiation after low-laser dose PDT. We investigated the effect 
of low–laser dose PDT on differentiation in the mouse osteoblast precursor cell line MC3T3-E1 and 
rat primary mesenchymal stromal cells. As a photosensitizer, we used 5-aminolevulinic acid (5-ALA), a 
biocompatible non-fluorescent heme precursor that induces synthesis and cellular accumulation of flu-
orescent protoporphyrin IX (PpIX)26. PDT is conventionally used to kill tumor cells; therefore, we first 
tested a range of light doses to establish optimal conditions for low-dose PDT that would not result in 
cell killing. Light doses of 1–3 J/cm2 caused no significant decrease in MC3T3-E1 cell viability 3 days after 
irradiation in the presence of 5-ALA (Supplementary Fig. S1), although a small but significant decrease 
in relative cell number was observed at 3 J/cm2 after 1 day. Laser energy densities above 4 J/cm2 resulted 
in more than 90% loss of cells viability.
After optimizing the conditions, we treated MC3T3-E1cells with low-dose PDT (light + 5-ALA) and 
examined the effect on calcium deposition as a surrogate marker of differentiation. Seven days after 
exposure to 3 J/cm2 in the presence of 5-ALA, MC3T3-E1 cells exhibited a significant increase in Alizarin 
red staining (Fig. 1a), which detects mineralized calcium. This effect was dependent on PDT dose: nei-
ther cells exposed to light in the absence of 5-ALA, nor cells exposed to lower doses of light in the 
presence of 5-ALA, exhibited elevated staining. Quantitation of the amount of deposited calcium using 
the methylxylenol blue (MXB) method revealed that cells exposed to low-dose PDT at 3 J/cm2 deposited 
26% more calcium than untreated cells (Fig. 1b). We further characterized these cells by measuring the 
expression of osteoblast differentiation markers. A transient increase in expression of secreted alkaline 
phosphatase (ALP), an early differentiation marker was observed following exposure of cells to low-dose 
PDT (Fig. 1c). The late differentiation marker osteocalcin began to rise in cells exposed to low-dose PDT, 
increasing to 2-fold over control after 10 days (Fig. 1d). Likewise, BMP-2 levels were elevated 2-fold 7 
days after treatment (Fig. 1e).
Inspired by our observations in osteoblasts, we performed similar experiments in primary rat mesen-
chymal stromal cells (MSCs) to determine if our findings can be generalized to other pluripotent stem 
cell types. As in the osteoblast precursor cells, low-dose PDT induced the MSCs to deposit calcium 
(Fig.  2a,b), express the early marker secreted ALP (Fig.  2c), and the late marker osteocalcin (Fig.  2d). 
Although the results were qualitatively similar in these two cell types, differentiation was slower in MSCs 
than in osteoblast precursors (e.g., compare Fig. 1d to Fig. 2d: osteoblast precursors expressed osteocal-
cin 10 days after PDT, whereas no significant increase in osteocalcin was observed in MSCs until day 14). 
Taken together, these data demonstrate that low-dose PDT induced osteoblast differentiation in osteo-
blast precursor cells and primary MSCs, as determined by both functional assays (calcium deposition) 
and expression of differentiation markers.
AP-1 mediates induction of osteoblast differentiation after low-dose PDT. Next, we sought 
to identify the critical factors involved in the osteoblast differentiation we observed in MC3T3-E1 cells 
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following low-dose PDT. Intracellular ROS imaging by using the fluorogenic probe revealed that intra-
cellular ROS was enhanced by low-dose PDT at 3 J/cm2 (Fig.  3). We investigated several transcription 
factors regulated by intracellular ROS levels: activator protein-1 (AP-1), which regulates gene expression 
in response to a variety of conditions including cellular stress27; NF-κ B, a major inducer of proinflam-
matory signaling28; HIF-1α , which mediates the response to hypoxia29; and STAT-3, which is involved 
in signaling in response to several cytokines and growth factor receptors30. Previous reports implicate 
each of these pathways in osteoblast differentiation. AP-1 promotes differentiation31,32, in part via pro-
tein–protein interactions with Runx233 and Smads34. By contrast, NF-κ B, HIF-1α , and STAT-3 have been 
reported to either stimulate or suppress differentiation depending on the context. NF-κ B is activated 
under conditions that promote osteogenic differentiation of human adipose tissue derived stromal cells 
via a subsequent increase of transcriptional coactivator with PDZ-binding motif (TAZ) expression35, 
whereas in other systems inhibition of NF-κ B leads to enhance Fra-1 expression in differentiated osteo-
blasts and is associated with increased bone matrix deposition and bone formation36. Hypoxia and other 
treatments that induce HIF-1α expression can elevate BMP-2 expression37 and promote calcium depo-
sition38, whereas hypoxia is reported to inhibit osteogenic differentiation in some cell types39. Similarly, 
STAT-3 has been reported to both stimulate and inhibit osteogenesis in mesenchymal stem cells40. We 
elected not to investigate two other ROS-regulated factors, p53 and Nrf2, because these proteins are 
involved in pathways exclusively shown to suppress osteoblast differentiation41,42.
Figure 1. Elevated calcium deposition and induction of osteoblast differentiation markers after low-
dose PDT. MC3T3-E1 osteoblast precursor cells were incubated for 3 hr with the indicated concentrations 
of 5-aminolevulinic acid (5-ALA), after which the drug was washed out and the cells were exposed to 0, 
1, 2, or 3 J/cm2 of laser energy (30 mW/cm2; λ = 635 nm). After PDT, cells were switched to differentiation 
medium (10 nM dexamethasone, 10 mM β -glycerophosphate, 50 μ g/ml ascorbic acid) and cultured for 7 
days. (a) Culture dishes were subjected to Alizarin red staining to detect deposited calcium. (b) Deposited 
calcium was quantitated using the methylxylenol blue (MXB) method and normalized against the level in 
untreated cells. *p < 0.01 vs. 0 mM 5-ALA + 3 J/cm2. (c) Levels of secreted alkaline phosphatase (ALP) in 
the culture medium, an early differentiation marker, detected using a fluorescence-based assay. (d) Levels of 
osteocalcin in the culture medium, a late differentiation marker, detected by ELISA. (e) Levels of BMP-2 in 
the culture medium, an osteoblast marker, detected by ELISA. *p < 0.01 vs. 0 mM 5-ALA + 3 J/cm2.
www.nature.com/scientificreports/
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In order to investigate AP-1 pathway activity, we stably transfected MC3T3-E1 cells with the 
pGreenFire-AP1 construct, which is activated by AP-1 transcription factor complexes, i.e., hetero- or 
homo-dimeric complexes of members of the proto-oncogene families Jun (c-Jun, JunB, JunD) and 
Fos (c-Fos, FosB). When activated, pGreenFire expresses both GFP and luciferase, enabling both 
fluorescence-microscopic detection via the GFP signal and quantitative transcription assays via the lucif-
erase signal. Exposure of the transfected cells to low-dose PDT activated the AP-1 pathway, as reflected 
by GFP (Fig. 4a) and luciferase expression (Fig. 4b). These data revealed that AP-1-mediated signalling 
is activated in cells treated with 3 J/cm2 of laser energy. In addition, the DNA binding activity of mul-
tiple proteins of the Fos and Jun families were significantly upregulated in cells treated with 3 J/cm2 of 
laser energy in the presence of 5-ALA (Fig. 4c). The elevation DNA binding activity of AP-1, especially 
those previously reported to be involved in bone formation, indicates that the transcriptional activity of 
pGreenFire is likely to represent bona fide activation of the AP-1 pathway.
Protein kinase C (PKC) induces AP-1–dependent transcription43, whereas interference with PKC 
activity, by expression of kinase-dead or dominant-negative PKC44 or overexpression of a PKC-interacting 
protein45, abrogates AP-1 activation. To confirm that AP-1 activation was critical for osteoblast differen-
tiation in PDT-treated cells, we exposed cells to PKC inhibitors and monitored the effect on osteoblast 
differentiation. Calcium deposition, as determined by Alizarin red staining, was significantly suppressed 
(Supplementary Fig. S2). Together, these findings demonstrate that the AP-1 pathway is activated by 
Figure 2. Low-dose PDT induces osteoblast differentiation in rat primary mesenchymal stromal cells. 
Rat primary mesenchymal stromal cells were incubated for 3 hr with the indicated concentrations of 
5-aminolevulinic acid (5-ALA), after which the drug was washed out and the cells were exposed to 0, 1, 
2, or 3 J/cm2 of laser energy (30 mW/cm2; λ = 635 nm). After PDT, cells were switched to differentiation 
medium (10 nM dexamethasone, 10 mM beta-glycerophosphate, 50 μ g/ml ascorbic acid), and cultured for the 
indicated times. (a) Fourteen days after PDT, culture dishes were subjected to Alizarin red staining to detect 
deposited calcium. (b) Fourteen days after PDT, deposited calcium was quantitated using the methylxylenol 
blue (MXB) method. (c) Levels of secreted alkaline phosphatase (ALP) in the culture medium, an early 
differentiation marker, detected using a fluorescence-based assay. (d) Levels of osteocalcin in the culture 
medium, a late differentiation marker, detected by ELISA. *p < 0.01 vs. 0 mM 5-ALA + 3 J/cm2.
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low-dose PDT, and that AP-1 activity is necessary for the induction of osteoblast differentiation following 
this treatment.
By contrast, none of the other factors we examined NF-κ B, HIF-1α , and STAT-3 appeared to be 
involved in PDT-induced differentiation. In contrast to previous reports46, phosphorylation of NF-κ B 
was not induced by low-dose PDT (Supplementary Fig. S3a), and an NF-κ B promoter-reporter construct 
was not activated (Supplementary Fig. S3b). Consistent with this, and in sharp contrast to the PKC 
inhibitor experiments described above, the NF-κ B inhibitor ammonium pyrrolidine dithiocarbamate had 
no effect on calcium deposition following low-dose PDT (Supplementary Fig. S3c). Likewise, HIF-1α 
was not expressed immediately after low dose PDT (Supplementary Fig. S4a), and the HIF-1α inhib-
itor 3-(2-(4-Adamantan-1-yl-phenoxy)-acetylamino)-4-hydroxybenzoic acid methyl ester had no effect 
on calcium deposition (Supplementary Fig. S4b). The levels of phosphorylated (i.e., activated) STAT-3 
declined significantly following PDT, consistent with a previous report47 (Supplementary Fig. S5). These 
data suggest that these major transcription-factor pathways regulated by ROS are not involved in osteo-
blast differentiation induced by low-dose PDT.
Figure 3. Intracellular ROS formation after low-dose PDT. MC3T3-E1 osteoblast precursor cells were 
incubated with CellROX reagent 30 min before low-dose PDT. CellROX reagent is non-fluorescent while in 
a reduced state and becomes fluorescent (red) upon oxidation by ROS. After low-dose PDT, cells were fixed 
and DAPI solution was added for the nuclear counterstain (blue). bar = 50 μ m.
www.nature.com/scientificreports/
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Discussion
The results of this study show that low-dose PDT promotes differentiation of osteoblast precursor cells 
and MSCs, as demonstrated by induction of calcium deposition and elevated expression of osteoblast 
differentiation markers (Figs 1 and 2). It is known that PpIX generated from exogeneous 5-ALA is local-
ized mainly in the mitchondria initially. At later time point it diffuseds out into the cytosol and is also 
localized in cell membranes48. Intracellular ROS was enhanced by low-dose PDT at 3 J/cm2 (Fig. 3) and 
AP-1–dependent transcription was significantly induced (Fig. 4a and 4b), and the DNA binding activity 
of AP-1 components (FosB, c-Fos, c-Jun, JunD, Fra-1, Fra2) were upregulated (Fig. 4c), suggesting that 
this transcription factor plays an important role in the observed differentiation. Furthermore, inhibition 
of PKC suppressed calcium deposition in response to low-dose PDT (Supplementary Fig. S2), consistent 
with a requirement for AP-1 in this process. While direct AP-1 blocking was not tested, the well estab-
lished relationship between PKC inhibition and AP-1 activation is consistent with our data.
The contribution of AP-1 to PDT-induced osteoblast differentiation is supported by several lines of 
evidence regarding the physiology and regulation of this transcription factor. First, AP-1 activity is upreg-
ulated by ROS49, possibly via stabilization of c-Fos and c-Jun transcripts or other post-transcriptional 
modifications50, and AP-1 activation is required for IL-10 production in response to PDT51. Although 
these previous studies focused on PDT regimens designed to kill tumor cells, a similar induction of AP-1 
activity occurred at the sub-lethal doses used in our experiments. Second, AP-1 is responsive to oxida-
tive stress52,53, suggesting that PDT may activate AP-1 by enhancing the formation of ROS within cells. 
Third, AP-1 exerts wide-ranging influences on pluripotency and differentiation. In addition to promoting 
Figure 4. Activation of the AP-1 pathway following low-dose PDT. MC3T3-E1 osteoblast precursor cells 
were stably transfected with pGreenFire-AP1, a GFP/luciferase dual reporter of AP-1 pathway activity, and 
otherwise treated as described for Fig. 1. All data shown in (a)–(c) were collected 1 hr after PDT. (a) GFP 
signal produced by pGreenFire-AP1, detected by fluorescence microscopy. bar = 50 μ m. (b) Quantitation of 
luciferase expressed from pGreenFire-AP1. PMA (positive control): cells were treated with 100 nM phorbol 
13-myristate 12-acetate for 30 min to induce AP-1 transcription factor activity. Luciferase activities are 
expressed in graphs as relative luciferase units (RLU). *p < 0.01 vs. 0 mM 5-ALA + 3 J/cm2. (c) DNA binding 
levels of the indicated Fos and Jun family member subunits of AP-1 dimeric complexes. *p < 0.05 vs. 0 mM 
5-ALA + 3 J/cm2.
www.nature.com/scientificreports/
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the survival and growth of a variety of cell types27, it also promotes differentiation and controls lineage 
decisions in BMSCs31. In particular, AP-1 has been implicated specifically in osteoblast differentiation. 
Fra-1 and Fra-2, members of the Fos family, mediate bone matrix deposition and bone formation, and 
knockout mice lacking these proteins exhibit abnormal bone growth54–56. Furthermore, AP-1 interacts 
physically with the osteoblast-specific transcription factor Runx233, and Fos and Jun family members are 
upregulated in response to TGF-β and BMP-2 in osteoblasts32. In light of these prior observations, our 
findings suggest that low-dose PDT enhances the formation of ROS, resulting in upregulation of AP-1 
activity, which then proceeds to activate expression of bone markers and promote bone differentiation. 
Based on these experimental data, a suggested illustration depicting the role of AP-1 in cell differentia-
tion after low-dose PDT is shown in Fig. 5. AP-1 is also reported as an important factor for regulating 
chondrocyte57 and adipocyte58 differentiation. Therefore, low-dose PDT-induced activation of AP-1 with 
the addition of appropriate differentiation medium to cells may regulate chondrocyte and adipocyte 
differentiation and warrant evaluation in subsequent studies.
Importantly, both HIF-1α and NF-κ B were not activated by low-dose PDT, and their activity did not 
appear to be essential for promotion of osteoblast differentiation (Supplementary Figs. S3 and S4). Under 
conventional (high-dose) PDT, HIF-1α accumulates as a result of hypoxia, either due to consumption of 
molecular oxygen in the tumor cells or collateral damage to adjacent tumor vasculature59, although the 
latter effect is not observed in vitro.
To date, PDT has been used primarily to treat cancer and diseases associated with neovascularization. 
However, the results described here demonstrate that PDT could provide an effective means of changing 
cell fate by serving as a ‘molecular switch’ for regulatory proteins. Especially if the methods described 
here prove applicable to additional cell types, PDT-induced differentiation could be useful in multiple 
contexts. In basic studies of disease mechanisms and pathways, the ability to promote differentiation by 
exposing cells to light and small-molecule drugs would enable highly efficient and rapid production of 
desired cell types for use in experimental manipulations. Such an abundant and reliable source of differ-
entiated cells could also be used to provide model cells for toxicity testing, novel target discovery, and 
drug-development studies. In the clinic, in vitro PDT-induced differentiation of precursor cells derived 
from patient tissues would decrease the waiting time required to obtain sufficient material for transplants 
or other procedures. PDT might even be used to promote in situ differentiation of precursor cells trans-
planted into diseased tissues or the patient’s own endogenous progenitor cells. Based on these potential 
uses, future studies should seek to demonstrate PDT-induced differentiation in an expanded range of 
cells, and to further characterize the molecular mechanisms underlying this phenomenon.
Figure 5. A proposed model for the osteoblast differentiation after low-dose PDT PDT activates AP-1 by 
enhancing the formation of ROS within cells. AP-1 exerts wide-ranging influences on cells differentiation.
www.nature.com/scientificreports/
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Methods
Cell culture. MC3T3-E1 cells (subclone 4, obtained from ATCC) were cultured in Minimum Essential 
Medium alpha (MEMα ) without ascorbic acid (Life Technologies, Inc.) supplemented with 10% fetal calf 
serum (FCS, Thermo Scientific HyClone). Rat MSCs (obtained as described in the following paragraph) 
were cultured in Dulbecco’s Modified Eagle medium (DMEM, Life Technologies, Inc.) supplemented 
with 15% FCS. All media were supplemented with 100 units/mL penicillin and 0.1 mg/mL streptomycin. 
Cell culture was performed at 37 °C.
Rat MSCs were isolated from the bone shaft of femurs of 3-week-old male Fisher 344 rats as previ-
ously described60. Briefly, both the ends of rat femurs were cut away from the epiphysis, and the bone 
marrow was flushed out using a syringe (21-gauge needle) containing 1 ml of DMEM supplemented 
with 15% FCS and 50 U/ml penicillin/streptomycin. The cell suspension was placed into culture dishes. 
The medium was changed on the fourth day of culture and every 3 days thereafter. When the cells pro-
liferated to subconfluence, usually after 7–10 days, they were detached by incubation for 5 min at 37 °C 
in phosphate-buffered saline (PBS, pH 7.4) containing 0.25% [w/v] trypsin/0.02% [w/v] EDTA. The 
cells were subcultured at a density of 2 × 104 cells/cm2; subconfluent cells of the second passage were 
used for all experiments. Cell-surface markers of rat MSCs were confirmed by flow cytometry (CD29+, 
CD90+, CD34−, CD45−). All animal procedures were performed according to protocols approved by the 
Massachusetts General Hospital Subcommittee on Research Animal Care (2008N000159).
Low-dose photodynamic therapy. Cells were seeded in 35-mm dishes (5 × 105 cells/dish), cul-
tured for 24 hr, and then cultured for 3 hr in 2 mL serum-free medium containing 0, 0.5, or 1.0 mM 
5-ALA. After the 5-ALA incubation, cells were gently washed three times in PBS, and the incubation 
was replaced with 2 mL serum-free medium. Irradiation was performed using a 635-nm diode laser 
(Model 7401, High Power Devices, Inc) at 30 mW/cm2 for 0, 34, 67 or 102 sec (0, 1, 2 or 3 J/cm2) using 
a fiber-coupled illumination stage. After irradiation, the medium was replaced with 2 mL differentiation 
medium (complete medium containing 10 nM dexamethasone, 10 mM β -glycerophosphate, and 50 μ g/
ml ascorbic acid) and cultured for various times.
Cell viability assays. After 1 day or 3 days of PDT, cells viability were quantitated by MTT assay, and 
then normalized against of cells viability in the untreated (0 mM 5-ALA + 0 J/cm2 from the same time 
point) sample on the same day.
Alizarin red staining of calcium deposition. To evaluate calcium deposition, cells were rinsed three 
times with PBS and fixed with 4% formalin in PBS. Fixed cells were incubated with a 1% Alizarin red-S 
(Sigma–Aldrich, Co., MO) in aqueous solution (pH 6.5) for 15 min at room temperature, and then rinsed 
five times with PBS. Macro pictures of 35-mm dishes were taken by a digital camera (LUMIX, Panasonic 
Corporation, Japan).
Quantification of calcium deposition. Cells were collected by scraping, centrifuged (100 g, 5 min), 
washed twice with PBS, and incubated overnight at 4 °C in hydrochloric acid solution. The calcium 
concentrations in the supernatants were determined by the methylxylenol blue (MXB) method using the 
Calcium E-test Wako (Wako Pure Chemical Industries, Osaka, Japan). After decalcification, the cells were 
washed three times with PBS and solubilized with 0.1% (w/v) SDS solution. The protein concentrations 
in solubilized cells were measured using the BCA Protein Assay Kit (PIERCE Biotechnology, Inc., IL). 
The calcium content of the cell layer was normalized to protein content; normalized concentrations are 
expressed as “/mg protein” in each graph.
Protein detection. ALP activity in the culture medium was measured using the Alkaline Phosphatase 
Detection Kit, Fluorescence (Sigma–Aldrich, Co., MO). Other proteins were quantitated using com-
mercially available ELISA kits, as follows: Osteocalcin in the culture medium, Mouse Osteocalcin EIA 
Kit (for MC3T3-E1 cells) and Rat Osteocalcin EIA Kit (for rat MSCs) (Biomedical Technologies, Inc., 
MA); BMP-2 in the culture medium, Human/Mouse/Rat BMP-2 Quantikine ELISA Kit (R&D Systems, 
Inc., MN); NF-κ B p65, PathScan Phospho-NF-κ B p65 ELISA kit (Cell Signaling Technology, Inc., 
MA); HIF-1α ,  Human/Mouse Total HIF-1α DuoSet IC (R&D Systems, Inc., MN); STAT-3, PathScan® 
Phospho-Stat-3 (Tyr705) Sandwich ELISA Kit (Cell Signaling Technology, Inc., MA). For detection of 
NF-κ B, HIF-1α , and STAT-3, cells were washed three times with PBS and lysed using the cell lysis 
buffer according to the manufacturer’s instructions. All protein concentrations was normalized to protein 
content of the cell layer using the BCA Protein Assay Kit (PIERCE Biotechnology, Inc., IL); normalized 
concentrations are expressed as “/mg protein” in each graph.
ROS detection. Cells were seeded in 35-mm dishes (5 × 105 cells/dish), cultured for 24 hr, and then 
cultured for 3 hr in 2 mL serum-free medium containing 0, 0.5, or 1.0 mM 5-ALA. CellROX reagent (Life 
Technologies, Inc.) at a final concentration of 5 μ M was added to the cells and incubated for 30 min-
utes. After low-dose PDT, cells were fixed with 4% formaldehyde solution and DAPI solution (Life 
Technologies, Inc.) was added for the nuclear counterstain.The fluorescence imaging experiments were 
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carried out on the Keyence BZ-9000 microscope using a 20× objective. Light and photomultiplier tube 
settings were consistent across experimental groups.
AP-1 activity measurements. In order to investigate AP-1 pathway activity, pGreenFire-AP1-GFP- 
luciferase construct (System Biosciences, Inc., CA) was transfected into MC3T3-E1 cells using 
Lipofectamin 2000 (Life Technologies, Inc.). Seventy-two hours posttransfection, cells were seeded in 
96-well plates and were selected for G418 (Sigma–Aldrich, Co., MO) resistance. After low-dose PDT to 
transfected cells, GFP fluorescence imaging was obtained by the Olympus FV1000 microscope using a 
20× objective. Laser and photomultiplier tube settings were consistent across experimental groups. At 
the indicated times, supernatant was collected and luciferase activity was measured using the Bright-Glo 
Luciferase Assay System (Promega corporation, WI). Luciferase activities are expressed in graphs as 
relative luciferase units (RLU).
For the detection of DNA binding activity of AP-1 components (FosB, c-Fos, c-Jun, JunD, Fra-1, Fra2), 
AP-1 Family EZ-TFA Transcription Factor Assay Colorimetric (EMD Millipore, MA) was used. Cells 
were washed three times with PBS and lysed using the Nuclear Extraction Kit (EMD Millipore, MA). 
This assay kit detects specific transcription factor DNA binding activity in nuclear extract. It combines 
the principle of the electrophoresis mobility shift assay (EMSA) with the 96-well based enzyme-linked 
immune-sorbent assay (ELISA).
Statistical analysis. Data represented as mean ± the standard derivation of the mean. Statistical sig-
nificance (defined as P values of less than 0.01 or 0.05) was evaluated based on the unpaired Student’s 
t test (two-tailed). Values were determined in four or more independent experiments with samples col-
lected in triplicate for each experiment.
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